CJC-1295 No DAC / Ipamorelin

CAS: 863288-34-0 / 170851-70-4

|

SKU:CJC-1295 No DAC / Ipamorelin

CJC-1295 No DAC / Ipamorelin is a defined 1:1 peptide research blend composed of a growth hormone–releasing hormone (GHRH) analogue and a selective ghrelin-receptor agonist, developed for laboratory investigation of dual-pathway somatotroph signaling in controlled research environments.

Current Lot ID
2602-C119-10-001
Third-party analytical validation via HPLC & MS / Sequence matching verified

Research Use Only

This product is intended for research purposes only.

Configure Order

Select quantity and verify pricing.
SELECT CONCENTRATION
VOLUME PRICING
1
Technical Specification

Scientific Context & Applications

Research Profile Access

View extended technical data, molecular targets, signaling pathways, and historical research timelines for CJC-1295 No DAC / Ipamorelin

Scientific Context
Molecular classification and background.

This research blend combines a GHRH analogue (CJC-1295 No DAC) with a selective ghrelin-receptor agonist (Ipamorelin) to enable investigation of complementary endocrine signaling pathways involved in growth hormone secretion. In experimental models, the dual-agent framework is used to examine:
  • GHRH-mediated somatotroph activation and vesicle synthesis signaling
  • Ghrelin-receptor–mediated membrane depolarization and exocytotic signaling
  • Coordination between signal priming and release initiation pathways
  • Temporal dynamics of pulsatile endocrine communication
All observations are derived from non-clinical laboratory models and interpreted strictly within molecular and physiological signaling frameworks.

Laboratory Applications
Experimental models and settings.

CJC-1295 No DAC / Ipamorelin is utilized in non-clinical research environments as a blended peptide system to investigate endocrine signaling interactions. Reported experimental applications include:
  • Dual-Pathway Signaling Models: Applied in endocrine cell systems to study coordinated activation of synthesis- and release-associated signaling pathways.
  • Pulsatile Secretion Analysis: Used in laboratory models to examine temporal characteristics of secretory signaling, including burst amplitude and frequency relationships.
  • Receptor Interaction Studies: Investigated to assess parallel engagement of GHRH and ghrelin receptor pathways within somatotroph populations.
  • Systems-Level Endocrine Modeling: Applied in experimental frameworks evaluating network-level responses to concurrent peptide signaling inputs.

Scientific References
Peer-reviewed literature data.

  • Raun K, et al. (Raun K, et al.).“Ipamorelin pharmacology.”European Journal of Endocrinology
  • Teichman SL, et al. (Teichman SL, et al.).“Prolonged GHRH analog.”JCEM
  • Bowers CY. (Bowers CY.).“Growth hormone-releasing peptide.”Journal of Pediatric Endocrinology
  • Giustina A, et al. (Giustina A, et al.).“Regulation of growth hormone secretion.”Endocrine Reviews

Related Research Compounds

Explore compounds frequently investigated in similar research domains and signaling pathways.

GLP2-T

2023788-19-2

Thymosin Alpha-1 (TA1)

62304-98-7

Tesamorelin

218949-48-5

Selank

129954-34-3

GLP3-R

2381089-83-2

PT-141

189691-06-3